Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: PreDiabetes
Interventions: Low-dose bitter melon, High-dose bitter melon, Placebo; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Gardens, Florida • Port Saint Lucie, Florida • Addison, Illinois

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis
Interventions: Romosozumab, Alendronate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Participants
Interventions: DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Perimenopausal Depression
Interventions: Estradiol, Progesterone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 44 Years to 55 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Brain Death, Anoxic Brain Injury, Cardiac Arrest, Sedative Intoxication, Narcotic Intoxication
Interventions: Flumazenil, Naloxone; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 94
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Platelet Aggregation, ADP Blockers
Interventions: platelet aggregation measurement; Other
Lead sponsor: Aggredyne, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Irritable Bowel Syndrome
Interventions: asimadoline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Drug Hypersensitivity
Interventions: Penicillin allergy testing; Other
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Albany, New York

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Labor Pain
Interventions: Programmed Intermittent Epidural Bolus (PIEB); Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions: ABT-335, Placebo, Atorvastatin; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 45 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 124
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more

Conditions: Cleaning Product Causing Toxic Effect
Interventions: Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol; Device · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypercapnia, Ventilatory Depression
Interventions: Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 2,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 51
States / cities: Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: 30% Nitrous oxide, 0.4% Sevoflurane, 0.2% sevoflurane, Placebo; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fabry Disease
Interventions: PRX-102 1 mg/kg every two weeks; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 6
States / cities: Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Tacrolimus, Healthy Volunteers
Interventions: isavuconazole, tacrolimus; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Type 2 Diabetes
Interventions: protein supplement; Dietary Supplement
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bioequivalence
Interventions: Tacrolimus; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Effects of Bitter Melon on Cardiometabolic Health

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Romosozumab in Women With Chronic SCI

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

Perimenopausal Effects of Estradiol on Reward Responsiveness

Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Aggreguide A-100 ADP Assay Evaluation

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

Allergy Testing of Patients Labeled as Penicillin Allergic

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Programmed Intermittent Epidural Bolus Time Interval and Injection Volume

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

AvenovaTM as a Sterile Skin Preparation Agent

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Drug Interaction Study of Isavuconazole and Tacrolimus

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers